PSMA-RADS 2.0 Calculator for PSMA PET/CT

PSMA-RADS 2.0, or the Prostate-specific Membrane Antigen Reporting and Data System version 2.0, provides a structured framework for classifying individual findings on PSMA PET/CT according to their likelihood of representing prostate cancer involvement. The updated system retains the general PSMA-RADS 1 through 5 structure while refining indeterminate lesions, adding a category for treated metastases, and emphasizing an overall scan-level RADS score.^[1]

A PSMA-RADS calculator can help apply the published classification consistently, but the assigned category should be interpreted together with lesion location, uptake intensity, anatomic imaging, disease distribution, prior treatment, PSA history, and the overall clinical context. PSMA uptake is not specific to prostate cancer, and both benign processes and other malignancies can demonstrate radiotracer uptake.^[1]

PSMA-RADS 2.0 categories

The system ranges from findings considered benign or likely benign to lesions with imaging features strongly favoring prostate cancer. PSMA-RADS 3 contains four subcategories for findings that remain indeterminate or require additional evaluation.

Understanding PSMA-RADS 3A, 3B, 3C, and 3D

The PSMA-RADS 3 categories are particularly important because they represent lesions for which the true nature remains uncertain. PSMA-RADS 3A applies to equivocal uptake in soft tissue at a location typical for prostate cancer, while PSMA-RADS 3B applies to equivocal osseous uptake that could represent metastatic disease.^[1]

When clinically relevant and technically feasible, further characterization of a PSMA-RADS 3A or 3B lesion may include biopsy, another imaging modality, or interval imaging. The PSMA-RADS 2.0 publication suggests an initial follow-up interval of 3 to 6 months for PSMA-RADS 3A lesions when follow-up rather than biopsy is selected. Progression in lesion size or uptake can support subsequent recategorization.^[1]

PSMA-RADS 3C describes a different problem: intense uptake occurring at a site that is highly atypical for prostate cancer in the given clinical setting. Because other malignancies and nonprostatic processes may express PSMA, these lesions generally warrant additional investigation. PSMA-RADS 3D applies to suspicious abnormalities on anatomic imaging that lack corresponding PSMA ligand uptake and therefore also require further characterization.^[1]

How disease distribution affects PSMA-RADS interpretation

PSMA-RADS 2.0 places greater emphasis on the patient's overall disease pattern. In patients with widespread metastatic disease, defined in the publication as more than five malignant lesions, equivocal PSMA-RADS 3A or 3B findings may, at the interpreting physician's discretion, be considered PSMA-RADS 4 when the overall distribution strongly favors additional prostate cancer involvement.^[1]

This context-dependent option should not be applied automatically. Lesion location, uptake pattern, anatomic findings, disease burden, and the potential effect of the classification on management remain relevant to the final interpretation.

PSMA-RADS 4 versus PSMA-RADS 5

Both PSMA-RADS 4 and 5 describe findings with intense focal uptake at sites typical for prostate cancer. The key distinction is the presence of an anatomic correlate. A PSMA-RADS 4 lesion lacks definitive confirmation on conventional imaging, such as intense uptake in a nonenlarged lymph node or bone without a clear structural abnormality. A PSMA-RADS 5 lesion has corresponding anatomic findings, such as an enlarged lymph node or a compatible sclerotic bone lesion.^[1]

PSMA-RADS 5T for treated metastatic lesions

PSMA-RADS 5T was introduced in version 2.0 to identify previously established metastatic lesions after treatment. These lesions may retain intense uptake, demonstrate reduced uptake, or show no meaningful residual uptake following therapy. The 5T category allows the known treated disease site to remain represented within the PSMA-RADS framework rather than being reclassified solely according to its post-treatment uptake.^[1]

Overall PSMA-RADS score

PSMA-RADS 2.0 also emphasizes an Overall RADS Score for the examination. In general, the overall score is determined by the highest PSMA-RADS category among the individual target lesions. For example, a scan containing both a PSMA-RADS 3A lesion and a PSMA-RADS 5 lesion would receive an overall score of PSMA-RADS 5.^[1]

PSMA-RADS 5T requires additional context on follow-up examinations. If a treated lesion is the only remaining finding, the overall score may be 5T. When lesions from other categories remain present, the highest active category determines the overall impression rather than 5T automatically taking precedence.^[1]

Important interpretation considerations

PSMA uptake is not synonymous with prostate cancer. Benign skeletal abnormalities, ganglia, inflammatory processes, infection, and other malignancies may demonstrate uptake. Conversely, some suspicious lesions may demonstrate little or no PSMA ligand uptake. PSMA-RADS therefore incorporates anatomic appearance, typical versus atypical distribution, uptake intensity, and clinical context rather than relying on uptake alone.^[1]

The PSMA-RADS 2.0 calculator should be used as a structured reference for applying the published categories. It does not replace review of the complete PSMA PET/CT examination or determine histopathology, staging, treatment eligibility, or management independently.

Frequently Asked Questions (FAQs)